<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> worsens outcome of <z:hpo ids='HP_0001297'>stroke</z:hpo> either in the clinical setting or in animal models </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, two focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> models, permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO, 3-4 h) and reversible MCAO (1 h <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> + 3 h reperfusion), under <z:e sem="disease" ids="C0851834" disease_type="Disease or Syndrome" abbrv="">hyperglycemic conditions</z:e> were compared </plain></SENT>
<SENT sid="2" pm="."><plain>Using 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining to define viable tissue, this resulted in the infarction area being confined primarily to the cerebral cortex in the permanent MCAO group, while it extended to the subcortical area in the reversible MCAO group, and the lesion areas were respectively 27.7 +/- 5.3% and 46.8 +/- 12.0% of the ipsilateral hemisphere (P = 0.012) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> accelerated the cerebral damage compared to normoglycemia and <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> pre-treatment maintained tissue viability during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of hyperglycemic MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>In conclusion, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> combined with either of the two MCAO models resulted in rapid infarction associated with increased <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The hyperglycemic models are suitable for pharmaceutical therapeutic studies of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> efficacy </plain></SENT>
</text></document>